289-95-2Relevant academic research and scientific papers
Nickel-Catalyzed Electrosynthesis of Aryl and Vinyl Phosphinates
Daili, Farah,Ouarti, Abdelhakim,Pinaud, Marine,Kribii, Ibtihal,Sengmany, Stéphane,Le Gall, Erwan,Léonel, Eric
supporting information, p. 3452 - 3455 (2020/05/25)
A mild and useful nickel-catalyzed electrochemical phosphonylation of aryl and vinyl bromides is described. We show that alkyl H-phenylphosphinates can be coupled electrochemically with functionalized aryl and vinyl bromides using very simple conditions (Fe/Ni anode, bench-stable nickel pre-catalyst, undivided cell, galvanostatic electrolysis) to furnish the corresponding aryl and vinyl phosphinates in satisfactory to good yields. Couplings can also be applied to heteroaromatic bromides with some limitations like increased propensity to hydro-dehalogenation.
Coupled heterogeneous photocatalysis using a P-TiO2-αFe2O3 catalyst and K2S2O8 for the efficient degradation of a sulfonamide mixture
Guzmán-Mar, Jorge L.,Hernández-Ramírez, Aracely,Hinojosa-Reyes, Laura,Mendiola-Alvarez, Sandra Y.,Palomino-Cabello, Carlos,Turnes-Palomino, Gemma
, (2020/03/18)
Phosphorous-doped Ti-Fe mixed oxide (P-TiO2-αFe2O3) catalysts were prepared by the microwave-assisted sol-gel route and characterized using XRD, SEM, N2 physisorption, UV–vis diffuse reflectance, FTIR, and XPS. P-TiO2-αFe2O3 was evaluated during the degradation of a sulfonamide mixture (5 mg/L, each) under visible light. The photocatalytic process was optimized with a face-centered central composite design. Under optimal conditions (0.5 wt% of αFe2O3, pH 10, and 0.75 g/L of catalyst loading), the sulfate radical advanced oxidation process was carried out using 5 mM K2S2O8 (PS). P doping shifted the light absorption of P-TiO2-αFe2O3 in the visible light range owing to substitutional doping, while the coupling of P-TiO2 with α-Fe2O3 enhanced the absorption in the visible range, which resulted in an increase in the lifetime of the charge carriers and in a superior photoactivity of the P-TiO2-αFe2O3 catalyst in comparison to that of TiO2. The mineralization yield of the sulfonamides (SNs) mixture was enhanced in the presence of an electron acceptor (SO4 ? [rad]), allowing nearly 69 % within 300 min with the P-TiO2-αFe2O3/PS system, while P-TiO2-αFe2O3 and K2S2O8 oxidation achieved only 27 % and 21 %, respectively. The biodegradability index was 0.48 using the P-TiO2-αFe2O3/PS system, indicating a less toxic effluent than the original compounds. Recycling tests demonstrated that P-TiO2-αFe2O3 exhibits good stability in activating PS for SNs degradation during three cycles. Two main intermediates (pyrimidine and hydroquinone) and their hydroxylated re-arrangements were detected during the degradation of the SNs by the coupled process. Oxalic, oxamic, sulfonic, and acetic acids were also identified as by-products from the degradation of the SNs.
Flow hydrodediazoniation of aromatic heterocycles
R?der, Liesa,Nicholls, Alexander J.,Baxendale, Ian R.
, (2019/06/05)
Continuous flow processing was applied for the rapid replacement of an aromatic amino group with a hydride. The approach was applied to a range of aromatic heterocycles, confirming the wide scope and substituent-tolerance of the processes. Flow equipment was utilized and the process optimised to overcome the problematically-unstable intermediates that have restricted yields in previous studies relying on batch procedures. Various common organic solvents were investigated as potential hydride sources. The approach has allowed key structures, such as amino-pyrazoles and aminopyridines, to be deaminated in good yield using a purely organic-soluble system.
Salicylic Acid-Catalyzed One-Pot Hydrodeamination of Aromatic Amines by tert-Butyl Nitrite in Tetrahydrofuran
Felipe-Blanco, Diego,Alonso, Francisco,Gonzalez-Gomez, Jose C.
supporting information, p. 2857 - 2863 (2017/08/23)
A significant acceleration in the hydrodeamination of in situ formed diazonium salts (from aromatic amines) has been observed in the presence of 10-mol% salicylic acid, using tetrahydrofuran as the hydrogen donor. The reaction proceeds efficiently at 20 °C for a wide range of substituted anilines, even at 10-mmol scale, without any other additive. The same protocol has been adapted to the selective deuterodeamination of some aromatic amines. Control experiments clearly show that aryl radicals are involved in the reaction mechanism. (Figure presented.).
Infrared spectra of pyrazine, pyrimidine and pyridazine in solid argon
Breda,Reva,Lapinski,Nowak,Fausto
, p. 193 - 206 (2007/10/03)
The vibrational spectra of monomeric diazines (pyrazine, pyrimidine and pyridazine) isolated in solid argon and of the neat crystalline phase of these compounds, at 10 K, are reported and discussed. Full assignment of the spectra is presented, providing evidence that the assignments of several bands previously undertaken for the compounds under other experimental conditions (e.g., gas phase, neat liquid or solution) shall be reconsidered. The interpretation of the experimental data is supported by extensive DFT calculations performed with the B3LYP functional and the 6-311++G(d,p) basis set and by comparison with the anharmonic vibrational calculations reported by Boese and Martin [J.Phys.Chem. A, 108 (2004) 3085] and Berezin et al. [Russian J.Phys.Chem., 79 (2005) 425; Opt.Spectrosc., 97 (2004) 201]. Spectra/structure correlations were extracted from the data, enabling to conclude that, while the π-electron systems in both pyrazine and pyrimidine rings are strongly delocalized over all heavy-atoms, in pyridazine the canonical form with one CC and two CN double bonds strongly predominates. Finally, the UV-induced photoisomerization of matrix isolated monomeric pyrazine to pyrimidine is reported.
Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
-
, (2008/06/13)
This invention provides novel arylindenopyridines and arylindenopyrimidines of the formula: wherein R1, R2, R3, R4, and X are as defined above, and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A2a receptors. This invention also provides therapeutic and prophylactic methods using the instant compounds and pharmaceutical compositions.
Aminopyrimidine and aminopyridine anti-inflammation agents
-
, (2008/06/13)
Aminopyrimidine and aminopyridine (I) compounds, compositions and methods useful in the treatment of inflammatory, metabolic or malignant conditions, are provided herein.
Inhibitors of protein kinase for the treatment of disease
-
, (2008/06/13)
The present invention is directed in part towards methods of modulating the function of protein kinases with phenol- and hydroxynaphthalene-based compounds. The methods incorporate cells that express a protein kinase. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to phenol- and hydroxynaphthalene-based compounds and pharmaceutical compositions comprising these compounds.
Adenosine A2a receptor antagonists
-
, (2008/06/13)
This invention relates to compounds having the structural formula I or pharmaceutically acceptable salts or solvates thereof, wherein R, R2 and R3 are as defined in the specification, pharmaceutical compositions thereof, and methods of treating stroke or central nervous system diseases by administering the compound of the present invention to a patient in need of such treatment.
Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
-
, (2008/06/13)
The present invention provide a compound of formula I or II: or a pharmaceutically acceptable derivative thereof, wherein R1, R2, R3, and R4 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli; and Src-family kinases, especially Src and Lck kinases. These compounds are also inhibitors of GSK3 and CDK2 kinases. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
